Cargando…

MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma

Biomarkers that predict response to lenalidomide maintenance therapy in patients with multiple myeloma (MM) have remained elusive. We have shown that immunomodulatory drugs (IMiDs) exert anti-MM activity via destabilization of MCT1 and CD147. In this study, cell samples of 654 patients with MM who r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stroh, Jacob, Seckinger, Anja, Heider, Michael, Rudelius, Martina, Eichner, Ruth, Schick, Markus, Slawska, Jolanta, Emde-Rajaratnam, Martina, Salwender, Hans, Bertsch, Uta, Goldschmidt, Hartmut, Weisel, Katja, Scheid, Christof, Keller, Ulrich, Hose, Dirk, Bassermann, Florian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Stimulus Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791591/ https://www.ncbi.nlm.nih.gov/pubmed/34768284 http://dx.doi.org/10.1182/bloodadvances.2021005532

Ejemplares similares

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial
por: Hose, Dirk, et al.
Publicado: (2019)

RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma
por: Emde-Rajaratnam, Martina, et al.
Publicado: (2023)

Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial
por: Schmitt, Michael, et al.
Publicado: (2016)

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
por: Mai, Elias K., et al.
Publicado: (2020)

Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
por: Mai, Elias K., et al.
Publicado: (2021)

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation
por: Merz, Maximilian, et al.
Publicado: (2017)

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2023)

A novel class of ZNF384 aberrations in acute leukemia
por: Zaliova, Marketa, et al.
Publicado: (2021)

Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells
por: Meißner, Tobias, et al.
Publicado: (2015)

Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma
por: Merz, Maximilian, et al.
Publicado: (2019)

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma
por: Salwender, Hans, et al.
Publicado: (2019)

Clinical care pathway for the evaluation of patients with suspected VITT after ChAdOx1 nCoV-19 vaccination
por: Lee, Agnes Y. Y., et al.
Publicado: (2022)

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial
por: Weisel, Katja C., et al.
Publicado: (2019)

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2016)

Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19
por: Guervilly, Christophe, et al.
Publicado: (2021)

The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A
por: Wu, Shang-Chuen, et al.
Publicado: (2021)

Impact of sickle cell trait on morbidity and mortality from SARS-CoV-2 infection
por: Merz, Lauren E., et al.
Publicado: (2021)

IL-6 antagonists to replace systemic corticosteroids as the preferred anti-inflammatory therapy in patients with COVID-19?
por: Kow, Chia Siang, et al.
Publicado: (2022)

COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
por: Busca, Alessandro, et al.
Publicado: (2022)

Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP
por: De Waele, Laure, et al.
Publicado: (2021)

Rational biomarker development for the early and minimally invasive monitoring of AML
por: Abdelhamed, Sherif, et al.
Publicado: (2021)

TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes
por: Gurnari, Carmelo, et al.
Publicado: (2022)

JMML tumor cells disrupt normal hematopoietic stem cells by imposing inflammatory stress through overproduction of IL-1β
por: Yan, Yuhan, et al.
Publicado: (2022)

Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity
por: Fernández-Rodríguez, Concepción, et al.
Publicado: (2022)

Coevolving JAK2(V617F+)relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case
por: Penter, Livius, et al.
Publicado: (2021)

Molecular diagnosis of T-cell lymphoma: a correlative study of PCR-based T-cell clonality assessment and targeted NGS
por: Syrykh, Charlotte, et al.
Publicado: (2021)

Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti–PD-1–based therapy
por: Abbas, Hussein A., et al.
Publicado: (2021)

RNA sequencing of chronic GVHD skin lesions defines shared and unique inflammatory pathways characterizing lichen planus and morphea
por: Zouali, Habib, et al.
Publicado: (2022)

Day 30 SUV(max) predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy
por: Al Zaki, Ajlan, et al.
Publicado: (2022)

Live imaging of platelets and neutrophils during antibody-mediated neurovascular thrombosis
por: Laroche, Audree, et al.
Publicado: (2022)

The CLL comorbidity index in a population-based cohort: a tool for clinical care and research
por: Rotbain, Emelie C., et al.
Publicado: (2022)

Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern
por: Li, Maggie, et al.
Publicado: (2022)

Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors
por: Thompson, Ella R., et al.
Publicado: (2022)

CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies
por: Hu, Yixin, et al.
Publicado: (2022)

Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth
por: Lemaitre, Léa, et al.
Publicado: (2022)

Anti–IL-6 cytokine treatment has no impact on elevated hematocrit or splenomegaly in a polycythemia vera mouse model
por: Baldauf, Conny K., et al.
Publicado: (2022)

Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms
por: Alkhateeb, Hassan B., et al.
Publicado: (2022)

Multiple myeloma cells depend on the DDI2/NRF1-mediated proteasome stress response for survival
por: Chen, Tianzeng, et al.
Publicado: (2022)

VpreB surrogate light chain expression in B-lineage ALL: a report from the Children’s Oncology Group
por: Winter, Stuart S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mhorquiarh2io2j7vsbh0pej9q